LPCN — Lipocine Income Statement
0.000.00%
- $30.22m
- $5.58m
- -$2.85m
- 33
- 22
- 94
- 48
Annual income statement for Lipocine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.165 | 0 | 16.1 | 0.5 | -2.85 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 13.1 | 17.8 | 17 | 12.4 | 15.1 |
Operating Profit | -12.9 | -17.8 | -0.855 | -11.9 | -17.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13 | -21 | -0.634 | -10.8 | -16.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13 | -21 | -0.634 | -10.8 | -16.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -13 | -21 | -0.634 | -10.8 | -16.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13 | -21 | -0.634 | -10.8 | -16.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -8.54 | -6.45 | 0.384 | -2.09 | -3.1 |